Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on August 2, 2012. The report discloses the issuance of a press release regarding financial results for the fiscal quarter ended June 30, 2012.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the provided text.
Material Changes
The filing does not contain specific data to compare current period results against prior comparable periods. It serves solely as a notification that the Q2 2012 results have been announced.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding commercial and technology progress. Management highlights the following risks that could cause actual results to vary:
- Changes in regulatory clinical and guideline developments.
- Insufficient scientific data to meet regulatory standards or obtain required approvals.
- Inability to replicate clinical results in actual patient settings.
- Challenges to patent protection by competitors.
- Market size and product penetration falling short of expectations.
- Insufficient revenues to fund further development and clinical studies.
- Uncertainty in meeting future capital needs and obtaining additional funding.
- Varying product formulations and diverse regulatory requirements across different countries.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in the full text of the August 2, 2012 press release (Exhibit 99.1).
- Confirm the company's cash position and runway for future operations.
- Review the status of regulatory approvals for key products mentioned in the press release.
- Check for any updates on capital raising activities or debt obligations not detailed in this summary.